Clinical Trials

Status
Published

Recently Activated

SHOW MORE
Open
Accrual
2%
SWOG Clinical Trial Number
S1800D

A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

Status Notes
S1800D will open to accrual February 15, 2022, effective 12:00 pm PST. This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
02-15-2022
Open
Phase
II-III
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Status Notes
This study is open to accrual on December 21, 2021.
Research Committee(s)
Lung Cancer
Activated
12-21-2021
Open
Phase
II-III
Accrual
0%
SWOG Clinical Trial Number
S2012

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Status Notes
Activation: Effective December 02, 2021 at 2:00 p.m. Eastern.
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12-02-2021
ClinicalTrials.gov Registry Number
NCT05058651
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S2011

Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL

Status Notes
The study referenced above is open for participant accrual effective October 6th, 2021, at 12:00 p.m. Eastern Time.
Research Committee(s)
Genitourinary Cancer
Activated
10-06-2021
ClinicalTrials.gov Registry Number
04871529
Open
Accrual
0%
SWOG Clinical Trial Number
S1934

NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer

Status Notes
S1934 will reactivate 02/15/2022.
Research Committee(s)
Lung Cancer
Activated
09-09-2021
ClinicalTrials.gov Registry Number
04989283
Open
Phase
II
Accrual
12%
SWOG Clinical Trial Number
S2013

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Status Notes
S2013 will open to accrual on August 16, 2021, effective 12:00 pm PST.
Research Committee(s)
Symptom Control and Quality of Life
Activated
08-16-2021